Testosterone Recovery After Prolonged Androgen Suppression in Patients With Prostate Cancer

Journal of Urology

Volumn 180, Issue 4, 2008, Pages 1438-1444

  Yoon, Frederick H ^a   Gardner, Sandra L ^a   Danjoux, Cyril ^a   Morton, Gerard ^a   Cheung, Patrick ^a   Choo, Richard ^b  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b MAYO CLINIC   (United States)

Author keywords

androgens; recovery of function; testosterone

Indexed keywords

ANDROGEN; BUSERELIN; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ANDROGEN SUPPRESSION THERAPY; ANDROGEN THERAPY; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CASTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION;

ADULT; AGE FACTORS; AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY, NEEDLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LONG-TERM CARE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROBABILITY; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RECOVERY OF FUNCTION; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; TESTOSTERONE; TREATMENT OUTCOME;

EID: 50949087279     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.06.029     Document Type: Article

References (17)

1. Wang C., Catlin D.H., Demers L.M., Starcevic B., and Swerdloff. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 89 (2004) 534
2. Sharifi R., Bruskewitz R.C., Gittleman M.C., Graham S.D., Hudson Jr. P.B., and Stein B. Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer. Clin Ther 18 (1996) 647
3. Pintilie M. Competing Risks: A Practical Perspective (2006), John Wiley & Sons Ltd, Hoboken, New Jersey
4. Kalbfleisch J.D., and Prentice R.L. The Statistical Analysis of Failure Time Data (1980), John Wiley & Sons Inc, Hoboken, New Jersey
5. Hall M.C., Fritzsch R.J., Sagalowsky A.I., Ahrens A., Petty B., and Roehrborn C.G. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Urology 53 (1999) 898
6. Oefelein M.G., and Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 164 (2000) 726
7. Pickles T., and Graham P. What happens to testosterone after prostate radiation monotherapy and does it matter?. J Urol 167 (2002) 2448
8. Zagars G.K., and Pollack A. Serum testosterone levels after external beam radiation for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 39 (1997) 85
9. Wilke D.R., Parker C., Andonowski A., Tsuji D., Catton C., Gospodarowicz M., et al. Testosterone and erectile function recovery after radiotherapy and long-term androgen deprivation with luteinizing hormone-releasing hormone agonists. BJU Int 97 (2006) 963
10. Kaku H., Saika T., Tsushima T., Ebara S., Senoh T., Yamato T., et al. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Prostate 66 (2006) 439
11. Morley J.E., Kaiser F.E., Perry III H.M., Patrick P., Morley P.M., Stauber P.M., et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 46 (1997) 410
12. Plymate S.R., Tenover J.S., and Bremner W.J. Circadian variation in testosterone, sex hormone-binding globulin, and calculated non-sex hormone-binding globulin bound testosterone in healthy young and elderly men. J Androl 10 (1989) 366
13. Nejat R.J., Rashid H.H., Bagiella E., Katz A.E., and Benson M.C. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. J Urol 164 (2000) 1891
14. Pickles T., Agranovich A., Berthelet E., Duncan G.G., Keyes M., Kwan W., et al. Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma. Cancer 94 (2002) 362
15. Montgomery B.T., Young C.Y., Bilhartz D.L., Andrews P.E., Prescott J.L., Thompson N.F., et al. Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP. Prostate 21 (1992) 63
16. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 37 (1997) 1035
17. Roach III M., Hanks G., Thames Jr. H., Schellhammer P., Shipley W.U., Sokol G.H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965